The new center focuses on utilizing a patient’s own biological resources to support healing, a field that has gained significant traction in orthopedic research. By harvesting and concentrating a patient’s adipose-derived cells or platelets, the medical team aims to offer targeted interventions for those who may not require immediate surgery. Dr. Samuel A. Joseph, Jr., the founder of the institute, emphasized that these treatments are not universal solutions and require rigorous patient selection through comprehensive diagnostic evaluations.

While the institute is leaning into these emerging therapies, it acknowledges the evolving regulatory landscape surrounding regenerative medicine. The facility maintains a policy of transparency regarding the current state of clinical evidence and FDA regulatory requirements for adipose-derived products. This expansion complements the institute’s existing suite of robotic-assisted and endoscopic surgical capabilities, allowing physicians to calibrate care plans between conservative management and advanced operative solutions depending on the specific needs of each patient.